"Blast Crisis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.
| Descriptor ID |
D001752
|
| MeSH Number(s) |
C04.557.337.539.250.100 C04.697.098.500.110 C15.378.190.636.370.100 C23.550.727.098.500.110
|
| Concept/Terms |
Blast Crisis- Blast Crisis
- Blast Crises
- Crises, Blast
- Crisis, Blast
- Blast Phase
- Blast Phases
- Phase, Blast
- Phases, Blast
|
Below are MeSH descriptors whose meaning is more general than "Blast Crisis".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Leukemia [C04.557.337]
- Leukemia, Myeloid [C04.557.337.539]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C04.557.337.539.250]
- Blast Crisis [C04.557.337.539.250.100]
- Neoplastic Processes [C04.697]
- Carcinogenesis [C04.697.098]
- Cell Transformation, Neoplastic [C04.697.098.500]
- Blast Crisis [C04.697.098.500.110]
- Hemic and Lymphatic Diseases [C15]
- Hematologic Diseases [C15.378]
- Bone Marrow Diseases [C15.378.190]
- Myeloproliferative Disorders [C15.378.190.636]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C15.378.190.636.370]
- Blast Crisis [C15.378.190.636.370.100]
- Pathological Conditions, Signs and Symptoms [C23]
- Pathologic Processes [C23.550]
- Neoplastic Processes [C23.550.727]
- Carcinogenesis [C23.550.727.098]
- Cell Transformation, Neoplastic [C23.550.727.098.500]
- Blast Crisis [C23.550.727.098.500.110]
Below are MeSH descriptors whose meaning is more specific than "Blast Crisis".
This graph shows the total number of publications written about "Blast Crisis" by people in this website by year, and whether "Blast Crisis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 1 | 1 | 2 |
| 1999 | 0 | 2 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Blast Crisis" by people in Profiles.
-
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era. Blood Adv. 2024 Jul 09; 8(13):3468-3477.
-
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 02; 22(1):43-69.
-
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors. Curr Hematol Malig Rep. 2023 06; 18(3):41-55.
-
SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It. Clin Lymphoma Myeloma Leuk. 2023 05; 23(5):303-309.
-
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv. 2020 10 27; 4(20):5246-5256.
-
Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. Int J Lab Hematol. 2020 Aug; 42(4):418-422.
-
How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2018 11 29; 132(22):2339-2350.
-
Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions. Cancer Genet. 2015 Jul-Aug; 208(7-8):396-403.
-
Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood. 2013 Jun 13; 121(24):4821-31.
-
Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. J Hematol Oncol. 2013 Mar 16; 6:21.